The report provides detailed analysis and forecasts of the global wind power market and the Canada wind market in particular. It also helps in analyzing and forecasting key metrics relating to the installed capacities, market size and growth.

Mumbai, Maharashtra -- (SBWIRE) -- 05/27/2010 -- The report provides detailed analysis and forecasts of the global wind power market and the Canada wind market in particular. It also helps in analyzing and forecasting key metrics relating to the installed capacities, market size and growth. The report facilitates to understand onshore and offshore market in Canada. It provides information relating to the major wind farms onshore and offshore projects and also the upcoming projects in Canada. The report helps to comprehend the wind turbine industry and the regulatory framework regarding the wind market in Canada. It offers interesting results on the market share of the top manufacturers in the Canada wind turbine industry. Additionally, it also provides ten profiles of the major wind turbine companies in Canada. The report also provides trends and analysis of investments in the Canada wind power market as well as deal summary and news flow for the last 6 months. On an all, it helps an investor to gauge the market and technological development of the Canada wind market.

Scope

Canada Wind Market Overview, Market Size and Growth
Predict and forecast future wind industry trends in Canada
Review of the wind turbine market, wind farms etc
Key policies and regulatory framework supporting the Canada Wind Market
Identify growth segments and opportunities in the Canada Wind Industry
Canada Wind Turbine Industry and the leading players in the Canadian wind market. Key companies covered include Enercon GmbH, Vestas Wind Systems A/S, GE Energy,Finavera Renewables Inc., Renewable Energy Systems Ltd, EarthFirst Canada Inc., Acciona Energia, S.A. and AIM PowerGen Corporation
Key details regarding the active and upcoming wind projects in Canada
Reasons to buy
Gain the most up to date and in-depth information on the Canada wind power market
Analyzes the Canada Wind Turbine Industry
Identify the key growth and investment opportunities within the Canada market based on the deal analysis
Facilitate decision-making based on strong historic and forecast data, deal analysis and recent developments
Develop strategies based on the latest operational and regulatory events in Canada
Rapidly help to prepare more detailed and effective planning materials
Understand and respond to your competitors' business structure, strategy and prospects
Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market
Identify and analyze the strengths and weaknesses of the leading wind companies in Canada
Companies Mentioned

Enercon GmbH,
Vestas Wind Systems A/S,
GE Energy,
Finavera Renewables Inc.,
Renewable Energy Systems Ltd,
EarthFirst Canada Inc.,
Acciona Energia, S.A.,
AIM PowerGen Corporation,
Naturener, S.A.,
TransAlta Wind,
Canadian Hydro Developers,
EPCOR Power L.P.,

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/2542/Canada-Wind-Energy-Market-Analysis-and-Forecasts-to-2013.html

For more information on this press release visit: http://www.releasewire.com/press-releases/release-45601.htm

Mumbai, Maharashtra -- (SBWIRE) -- 05/27/2010 -- Pharmaceutical and healthcare report," Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016" provides essential source of information and analysis on the global allergic conjunctivitis market. The report identifies the key trends shaping and driving the global allergic conjunctivitis market. The report also provides insights into the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights into the pipeline products within the global allergic conjunctivitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current allergic conjunctivitis market is dominated by brands, generics and off-label formulations which have high patient affordability, and there is strong competition. The pipeline for allergic conjunctivitis lacks innovation and has 17 molecules in clinical development. Allergic conjunctivitis market has low unmet needs as the market is well served by the currently available different treatment options from different classes of therapies

Scope

The scope of the report includes:

Annualized global allergic conjunctivitis market revenues data from 2001 to 2009, forecast for seven years to 2016.
Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include antihistamines/anti-allergic drugs which account for the largest share of the pipeline fallowed by immunosuppressants, NSAIDs, immunotherapy and PDE4 (Phosphodiesterase type 4) inhibitors.
Analysis of the current and future market competition in the global allergic conjunctivitis market. The key market players covered are Novagali Pharma SA, Fovea Pharmaceuticals SA, Cytos Biotechnology AG and Ono Pharmaceutical Co. Ltd.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future allergic conjunctivitis market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global allergic conjunctivitis market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What's the next big thing in the global allergic conjunctivitis market landscape? - Identify, understand and capitalize.

Companies Mentioned

Novagali Pharma S.A
Fovea Pharmaceuticals SA
Cytos Biotechnology AG
Ono Pharmaceutical Co. Ltd

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3184/Allergic-Conjunctivitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

For more information on this press release visit: http://www.releasewire.com/press-releases/release-45700.htm

Mumbai, Maharashtra -- (SBWIRE) -- 05/27/2010 -- The DC building power market is projected to grow significantly over the next several years, and among the driving forces is the need to improve efficiency and reduce electricity costs in several areas. According to the US Environmental Protection Agency (EPA), in 2006, data centers and servers in the United States accounted for approximately 1.5% of the nation's total electricity consumption. To put this in perspective, the EPA stated that this total exceeded the electricity consumed by the entire nation's color televisions, and is similar to the amount of electricity consumed by approximately 5.8 million average TV households. In addition, energy consumption in data centers in the US is projected to continue to grow, and double every five years.

Traditionally, large data centers and telecommunications facilities have consumed large amounts of electricity without much regard for energy efficiency. Due to the continuous need for energy production, it has been an acceptable practice to trade off energy efficiency and operating costs for the sake of system reliability. However, in recent years a number of factors have emerged that may change that practice. Now, a debate is taking place on how to cope with the growing need for electricity to power these facilities. Data center managers and other data center professionals are looking to dc power as an alternative solution to traditional ac power. Proponents of dc power claim that it has the potential to eliminate the biggest sources of energy loss and waste in traditional ac systems: the multiple back and forth transformations and conditioning needed to step voltage down for use by IT equipment.

One of the pressing needs for the further expansion of dc power was the establishment of dc voltage standards. In light of this need, two new dc power distribution standards for facilities were developed over the past year, one for high-voltage (380Vdc) applications and another for low-voltage (24Vdc) applications. The development of theses standards is significant and is expected to contribute to the further expansion of dc power. The 380Vdc standard was developed by the Electric Power Research Institute (EPRI) along with Lawrence Berkeley National Laboratories and is designed for data centers and other critical facilities. EPRI has developed the first dc voltage tolerance envelope plotting voltage variations versus time for 380-Vdc powered equipment. The new dc voltage tolerance envelope provides the technical details of the electrical operating environment, including allowable voltage surges and sags that could enable engineers to design power converters for use with 380-Vdc distribution systems for next-generation data center equipment.

The 24Vdc standard was developed by EMerge and is expected to play an important role in the expansion of dc power in commercial, industrial and residential buildings. The new EMerge Alliance standard is described as the first roadmap for the utilization of safe, low-voltage direct current power in commercial interiors. The EMerge Alliance Standard 1.0 establishes a more efficient means of powering the rapidly increasing number of digital, dc-powered devices, such as sensors, lighting and IT equipment found in today's workplaces. It creates an integrated, open platform for power, interior infrastructures, controls and a wide variety of peripheral devices to facilitate the hybrid use of ac and dc power within buildings.

As the emergence of the EMerge Alliance standard suggests, dc power can be used to improve efficiency at the lower-voltage levels. The addition of dc power delivery systems to homes, office building and commercial facilities offers the potential for significant improvements in energy delivery efficiency, reliability, power quality and cost of operation. Most of these facilities are currently dominated by fixed overhead lighting, and a variety of electrical devices that are typically wired for the building's lifetime rather than the occupant or residents evolving needs. In fact, although opportunities exist in both new installations and retrofits, according to the EMerge Alliance, 80% of the market opportunities are in the updating and retrofitting of commercial buildings. Actually, the ability to distribute low-voltage dc power within common infrastructures is already present in most commercial interiors

Lighting presents one of the major opportunities for the further development of dc power. According to a recent study funded by the U.S. Department of Energys Energy Efficiency and Renewable Energy Office (DOE EERE), lighting accounts for 22% of all electricity consumed in the United States. Commercial businesses consume 20% to 30% of their total energy just for lighting. And, 50% or more of that lighting-related energy may be wasted by obsolete equipment, inadequate maintenance or inefficient use. Upgrading lighting systems is one of the best energy efficiency investments available to a commercial facility. Since linear fluorescent light accounts for the majority of a commercial building's lighting energy use, improving the efficiency of these systems can save significant amounts of energy and money.

In addition to advances in dc power for data centers, new advances in solid-state lighting (SSL) are among the market forces expected to drive the dc power market over the next several years. The era SSL will be arriving soon, primarily powered by ultra-high-efficiency light emitting diodes (LEDs) and to a lesser extent by organic light emitting diodes (OLEDs). Used in large high-definition signs, architectural lighting, stadiums, billboards and other applications, modern LEDs represent the latest lighting devices based on dc power. In fact, current economic conditions are just right for the emerging LED replacement market. Several factors cited for this include "dramatic" improvements in commercially available LED performance, significant cost reduction, government regulations, and energy savings.

Other applications contributing to the advancement of dc power include common consumer electronics devices, which operate on dc power and require conversion from dc sources. These devices are common in every household and include televisions, computers, set top boxes and many others. (All microprocessors require direct current and many devices operate on direct power because it can be precisely regulated for sensitive components.) In fact, many of the smaller electronic devices such as mobile phones, notebook computers and personal digital assistants (PDAs) use ac-dc adapters, which also result in power loss during conversion. In aggregate, the millions of ac-dc conversions performed for the operation of these electronic devices extract a huge loss in energy during conversion.

In addition to the applications and trends driving the industry, the market for dc power is strongly influenced by a number of technological and regulatory factors. These factors vary from application to application and represent both opportunities and threats. They include the growth of dc power used in alternative energy systems, the availability of UL rated equipment and experienced personnel, the further development of both UPS technology, the expansion and development of a number of organizations and alliances the already-mentioned importance of increased efficiency and the further development of regulatory standards and policies.

Among the areas examined in this report are the technology and architecture trends affecting the industry, as well as a thorough discussion of new and emerging products and materials, potential threats and the latest regulatory developments and standards. Over 35 tables are presented depicting a variety of power system schematics and comparisons, architectural standards, product introductions, packaging solutions, efficiency standards and other relevant information. The focus of this comprehensive analysis provides decision makers with an insightful look into the current and future opportunities and threats available in the dc building power supply market.

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/2212/DC-Building-Power-Economic-Factors-Application-Drivers-Architecture-Technology-Standards-and-Regulatory-Developments.html

For more information on this press release visit: http://www.releasewire.com/press-releases/release-45599.htm

Mumbai, Maharashtra -- (SBWIRE) -- 05/27/2010 -- Pharmaceutical and healthcare report, "Stomach Cancer - Drug Pipeline Analysis and Market Forecasts to 2016", is an essential source of information and analysis on the global stomach cancer market. The report identifies the key trends shaping and driving the global stomach cancer market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products in the global stomach cancer segment.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's analysis suggests that the global gastric cancer market is expected to value $1,313m in 2016. Most of the chemotherapies are already off-patent while Taxotere and Xeloda are expected to lose their patents during 2010 to 2011. Taxotere's generic version, produced by Hospira, has already been approved in Europe through the decentralized procedure. The market is expected to be driven by the increase in demand due to the launch of promising targeted therapies currently in the late stage of development. The pending approval of Herceptin in the US and Japan will also boost the revenues generated in the gastric cancer market. However, the new therapies are not expected go off-patent before 2016. Therefore, the market is expected to witness strong growth in market revenues in the forecast period.

Scope

The scope of the report includes:
Annualized global (gastrointestinal) stomach cancer market revenues data from 2001 to 2009, forecast for seven years to 2016.
Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
Pipeline analysis data split across different phases by mechanism of action and emerging trends. The key classes of mechanism of action are mTOR inhibitors, PARP inhibitors, microtubule inhibitors, VEGFR inhibitors, multiple tyrosine kinase inhibitors, Heat Shock Protein 90 inhibitors, Eg5 inhibitors, Farnesyl-OH-transferase inhibitors, angiogenesis inhibitors and combinations of several existing chemotherapies.
Analysis of the current and future competition in the global stomach cancer market. The key market players covered include GlaxoSmithKline, Novartis Pharmaceuticals, Merck & Co, Eli Lilly and Company, Amgen, Fresenius Biotech GmBH, ACT Biotech, Genta Incorporated and Bristol Myers-Squibb.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future stomach cancer market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global gastrointestinal (stomach) cancer market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global gastrointestinal (stomach) cancer market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What's the next big thing in the global gastrointestinal (stomach) cancer market landscape? - Identify, understand and capitalize.

Companies Mentioned

GlaxoSmithKline
Novartis Pharmaceuticals
Eli Lilly and Company
Merck & Co

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3180/Stomach-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

For more information on this press release visit: http://www.releasewire.com/press-releases/release-45602.htm